{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:50:19Z","timestamp":1758441019936,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01 HL061744","U01 HL061746","U01 HL061748","U01 HL063804"],"award-info":[{"award-number":["U01 HL061744","U01 HL061746","U01 HL061748","U01 HL063804"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010390","name":"Saint Louis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Glaxo"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.mayocp.2019.04.015","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T17:04:36Z","timestamp":1570208676000},"page":"2249-2262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["BARI 2D: A Reanalysis Focusing on Cardiovascular Events"],"prefix":"10.1016","volume":"94","author":[{"given":"Saul M.","family":"Genuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Vlachos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Mori","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bantle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard R.","family":"Chaitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl F.","family":"Kelsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Spencer B.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"McBane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-2269","authenticated-orcid":false,"given":"Edward Y.","family":"Sako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Steffes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-324X","authenticated-orcid":false,"given":"Robert L.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.mayocp.2019.04.015_bib1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/PL00002934","article-title":"Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes","volume":"44","author":"Morrish","year":"2001","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.mayocp.2019.04.015_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11154-010-9135-3","article-title":"Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting","volume":"11","author":"Aronson","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"10.1016\/j.mayocp.2019.04.015_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/M14-0808","article-title":"Coronary revascularization in diabetic patients: a systematic review and Bayesian network meta-analysis","volume":"161","author":"Tu","year":"2014","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2019.04.015_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11936-015-0377-y","article-title":"Comparison of coronary artery bypass graft surgery and percutaneous coronary intervention in patients with diabetes","volume":"17","author":"Toklu","year":"2015","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"22","key":"10.1016\/j.mayocp.2019.04.015_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2019.04.015_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2019.04.015_bib7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.mayocp.2019.04.015_bib8","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A\u00a0randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2019.04.015_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1152\/physrev.1995.75.3.473","article-title":"Pathophysiology of insulin resistance in human disease","volume":"75","author":"Reaven","year":"1995","journal-title":"Physiol Rev"},{"issue":"suppl A","key":"10.1016\/j.mayocp.2019.04.015_bib10","first-page":"A53","article-title":"Classical risk factors and emerging elements in the risk profile for coronary artery disease","volume":"19","author":"Gensini","year":"1998","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.mayocp.2019.04.015_bib11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1161\/01.CIR.103.17.2144","article-title":"Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study","volume":"103","author":"Valantine","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2019.04.015_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.mayocp.2019.04.015_bib13","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","article-title":"Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study","volume":"111","author":"Langenfeld","year":"2005","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.mayocp.2019.04.015_bib14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.mayocp.2019.04.015_bib15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.mayocp.2019.04.015_bib16","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/ATVBAHA.110.207696","article-title":"Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study","volume":"30","author":"Davidson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.04.015_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2006.02723.x","article-title":"Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus","volume":"66","author":"Kim","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.mayocp.2019.04.015_bib18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2005.03.041","article-title":"Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study","volume":"45","author":"Pf\u00fctzner","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.04.015_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","article-title":"Nonhypoglycemic effects of thiazolidinediones","volume":"134","author":"Parulkar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.mayocp.2019.04.015_bib20","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2019.04.015_bib21","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2337\/diacare.27.11.2654","article-title":"Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes","volume":"27","author":"Choi","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.mayocp.2019.04.015_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","article-title":"Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)","volume":"137","author":"Yaghi","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.mayocp.2019.04.015_bib23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.mayocp.2019.04.015_bib24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/labinvest.2012.74","article-title":"Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis","volume":"92","author":"Park","year":"2012","journal-title":"Lab Invest"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2019.04.015_bib25","first-page":"789","article-title":"The University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Part II: mortality results","volume":"19","author":"Klimt","year":"1970","journal-title":"Diabetes"},{"issue":"25","key":"10.1016\/j.mayocp.2019.04.015_bib26","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1161\/CIRCULATIONAHA.109.913111","article-title":"The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction","volume":"120","author":"Chaitman","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mayocp.2019.04.015_bib27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/CIRCULATIONAHA.110.014860","article-title":"Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"124","author":"Sobel","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.mayocp.2019.04.015_bib28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1161\/CIRCULATIONAHA.112.092973","article-title":"Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"126","author":"Brooks","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2019.04.015_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1464-5491.2005.01448.x","article-title":"Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes","volume":"22","author":"Johnson","year":"2005","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.mayocp.2019.04.015_bib30","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular disease events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.mayocp.2019.04.015_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mayocp.2019.04.015_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2005.01.068","article-title":"The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen","volume":"106","author":"Wilson","year":"2006","journal-title":"Int J Cardiol"},{"issue":"25","key":"10.1016\/j.mayocp.2019.04.015_bib33","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jacc.2011.08.057","article-title":"A\u00a0point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation","volume":"58","author":"Park","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.04.015_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2011.08.010","article-title":"Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study)","volume":"109","author":"Hermida","year":"2012","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.04.015_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/1047-2797(92)90095-8","article-title":"Update on fibrinogen as a cardiovascular risk factor","volume":"2","author":"Kannel","year":"1992","journal-title":"Ann Epidemiol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.04.015_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00043798-199506000-00004","article-title":"Fibrinogen and cardiovascular risk","volume":"2","author":"Heinrich","year":"1995","journal-title":"J\u00a0Cardiovasc Risk"},{"issue":"3","key":"10.1016\/j.mayocp.2019.04.015_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jvs.2007.05.035","article-title":"Fibrinogen and high-sensitive C-reactive protein as serologic predictors for perioperative cerebral microembolic lesions after carotid endarterectomy","volume":"46","author":"Heider","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"issue":"9713","key":"10.1016\/j.mayocp.2019.04.015_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mayocp.2019.04.015_bib39","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/dc09-0117","article-title":"GHb level and subsequent mortality among adults in the U.S","volume":"32","author":"Saydah","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.mayocp.2019.04.015_bib40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0908359","article-title":"Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults","volume":"362","author":"Selvin","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2019.04.015_bib41","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1161\/CIRCULATIONAHA.110.978247","volume":"123","author":"Dagenais","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2019.04.015_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diacare.23.1.64","article-title":"Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects","volume":"23","author":"Frias","year":"2000","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2019.04.015_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms","volume":"58","author":"Wiernsperger","year":"1999","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.mayocp.2019.04.015_bib44","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"issue":"1-2","key":"10.1016\/j.mayocp.2019.04.015_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.mce.2013.04.019","article-title":"Elevation of miR-221 and -222 in the internal mammary arteries of diabetic subjects and normalization with metformin","volume":"374","author":"Coleman","year":"2013","journal-title":"Mol Cell Endocrinol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:31:53Z","timestamp":1758418313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619303957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0025619619303957"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.04.015","relation":{},"ISSN":["0025-6196"],"issn-type":[{"type":"print","value":"0025-6196"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BARI 2D: A Reanalysis Focusing on Cardiovascular Events","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}